{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:28:33Z","timestamp":1793212113987,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd003715.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,9,28]],"date-time":"2016-09-28T00:00:00Z","timestamp":1475020800000}}],"reference-count":62,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003715.pub3","type":"journal-article","created":{"date-parts":[[2016,9,28]],"date-time":"2016-09-28T20:16:53Z","timestamp":1475093813000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease"],"prefix":"10.1002","volume":"2016","author":[{"given":"Anthony K","family":"Akobeng","sequence":"first","affiliation":[{"name":"Sidra Medical & Research Center; PO Box 26999 Doha Qatar"},{"name":"Weill Cornell Medical College; Doha Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongni","family":"Zhang","sequence":"additional","affiliation":[{"name":"University of Western Ontario; Schulich School of Medicine & Dentistry; London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morris","family":"Gordon","sequence":"additional","affiliation":[{"name":"University of Central Lancashire; School of Medicine and Dentistry; Preston UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials; Cochrane IBD Group; 100 Dundas Street, Suite 200 London ON Canada N6A 5B6"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,9,28]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD003715.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2036.1990.tb00449.x","article-title":"Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. International Mesalazine Study Group","volume":"4","author":"Anonymous","year":"1990","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD003715.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00004836-199504000-00008","article-title":"A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission","volume":"20","author":"Arber","year":"1995","journal-title":"Journal of Clinical Gastroenterology"},{"issue":"4 Part 2","key":"10.1002\/14651858.CD003715.pub3-BIB0003|cit3","first-page":"A646","article-title":"A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission","volume":"106","author":"Arber","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003715.pub3-BIB0004|cit4","first-page":"68","article-title":"Mesalazine (Pentasa) as prophylaxis in Crohn's disease. A multicenter, controlled trial","volume":"26","author":"Bondesen","year":"1991","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD003715.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.gcb.2008.07.007","article-title":"Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial","volume":"33","author":"Cezard","year":"2009","journal-title":"Gastroenterologie Clinique et Biologique"},{"key":"10.1002\/14651858.CD003715.pub3-BIB0006|cit6","first-page":"542","article-title":"Prevention of recurrence by mesalamine (PENTASA) in pediatric Crohn's disease. A multicentric double blind trial","volume":"36","author":"Cezard","year":"2003","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"key":"10.1002\/14651858.CD003715.pub3-BIB0007|cit7","first-page":"A670","article-title":"Oral 5-aminosalicylic acid (5-ASA) in the prevention of early relapse of Crohn's disease. Interim analysis of a multicenter double blind randomized placebo-controlled trial","volume":"106","author":"Franchis","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003715.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1046\/j.1365-2036.1997.00212.x","article-title":"Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease","volume":"11","author":"Franchis","year":"1997","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD003715.pub3-BIB0009|cit9","first-page":"251","article-title":"Maintenance treatment of Crohn's disease using orally administered mesalazine (Pentasa). A controlled multicenter study","volume":"29","author":"Gendre","year":"1993","journal-title":"Annals of Gastroenterology and Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD003715.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0016-5085(93)90411-5","article-title":"Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Therapeutiques des Inflammatoires Digestives (GETAID)","volume":"104","author":"Gendre","year":"1993","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD003715.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/gut.49.4.552","article-title":"Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study","volume":"49","author":"Mahmud","year":"2001","journal-title":"Gut"},{"key":"10.1002\/14651858.CD003715.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1053\/gast.1996.v110.pm8608877","article-title":"Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance","volume":"110","author":"Modigliani","year":"1996","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD003715.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0016-5085(92)90822-G","article-title":"Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group","volume":"103","author":"Prantera","year":"1992","journal-title":"Gastroenterology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD003715.pub3-BIB0014|cit14","first-page":"A924","article-title":"5-aminosalicylic acid (Pentasa) in the maintenance of remission of Crohn's disease","volume":"108","author":"Sutherland","year":"1995","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD003715.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/S0016-5085(97)70117-3","article-title":"A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group","volume":"112","author":"Sutherland","year":"1997","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD003715.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1365-2036.1995.tb00438.x","article-title":"Mesalazine (Mesasal\/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease","volume":"9","author":"Thomson","year":"1995","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD003715.pub3-BIB0017|cit17","first-page":"71A","article-title":"New oral preparations for maintenance therapy in Crohn's disease","volume":"2","author":"Wellmann","year":"1988","journal-title":"Canadian Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD003715.pub3-BIB0019|cit18","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/00365521.1974.12096873","article-title":"The clinical effect of salazosulphapyridine (Salazopyrin r) in Crohn's disease. A controlled double-blind study","volume":"9","author":"Anthonisen","year":"1974","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"32","key":"10.1002\/14651858.CD003715.pub3-BIB0018|cit19","first-page":"1798","article-title":"Clinical effect of salazosulfapyridine (salazopyrin) in Crohn's disease. A controlled double-blind investigation","volume":"136","author":"Anthonisen","year":"1974","journal-title":"Ugeskrift for Laeger"},{"issue":"4","key":"10.1002\/14651858.CD003715.pub3-BIB0020|cit20","first-page":"200","article-title":"5-aminosalicylic acid in the prevention of relapses of Crohn's disease in remission: a long-term study","volume":"11","author":"Bresci","year":"1991","journal-title":"International Journal of Clinical Pharmacology Research"},{"issue":"4","key":"10.1002\/14651858.CD003715.pub3-BIB0021|cit21","first-page":"133","article-title":"Long-term therapy with 5-aminosalicylic acid in Crohn's disease: is it useful? Our four years experience","volume":"14","author":"Bresci","year":"1994","journal-title":"International Journal of Clinical Pharmacology Research"},{"issue":"1","key":"10.1002\/14651858.CD003715.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF01308338","article-title":"Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease","volume":"37","author":"Brignola","year":"1992","journal-title":"Digestive Diseases and Sciences"},{"issue":"5","key":"10.1002\/14651858.CD003715.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1053\/gast.1997.v113.pm9352848","article-title":"Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables","volume":"113","author":"Camma","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003715.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/978-3-642-85451-4_235","article-title":"Prevention of recurrence by salazosulfapyridine (azulfidine) therapy in Crohn's disease. A double blind study","volume":"82","author":"Ewe","year":"1976","journal-title":"Verhandlungen der Deutschen Gesellschaft fur Innere Medizin"},{"issue":"9","key":"10.1002\/14651858.CD003715.pub3-BIB0025|cit25","first-page":"1343","article-title":"Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group","volume":"88","author":"Hanauer","year":"1993","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD003715.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/gut.18.1.69","article-title":"Sulphasalazine in asymptomatic Crohn\u2019s disease","volume":"18","author":"Lennard-Jones","year":"1977","journal-title":"Gut"},{"key":"10.1002\/14651858.CD003715.pub3-BIB0027|cit27","first-page":"A661","article-title":"Experience with delayed-release mesalamine for maintenance of remission of Crohn's disease (CD)","volume":"1","author":"Lichtenstein","year":"2009","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD003715.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"92","DOI":"10.7326\/ACPJC-2002-136-3-092","article-title":"Olsalazine was not better than placebo in maintaining remission in inactive Crohn disease","volume":"136","author":"Luthra","year":"2002","journal-title":"ACP Journal Club"},{"issue":"Suppl","key":"10.1002\/14651858.CD003715.pub3-BIB0029|cit29","first-page":"45","article-title":"Further controlled trials of salazosulfapyridine in Crohn's disease","volume":"19","author":"Malchow","year":"1981","journal-title":"Zeitschrift fur Gastroenterologie"},{"issue":"2","key":"10.1002\/14651858.CD003715.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0016-5085(84)90409-8","article-title":"European cooperative Crohn's disease study (ECCDS): Results of drug treatment","volume":"86","author":"Malchow","year":"1984","journal-title":"Gastroenterology"},{"issue":"797","key":"10.1002\/14651858.CD003715.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/pgmj.68.797.189","article-title":"Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis?","volume":"68","author":"Nakshabendi","year":"1992","journal-title":"Postgraduate Medical Journal"},{"key":"10.1002\/14651858.CD003715.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1155\/1993\/729483","article-title":"Comparative trial of remission prophylaxis in quiescent Crohn's disease with oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets","volume":"7","author":"Howaldt","year":"1993","journal-title":"Canadian Journal of Gastroenterology"},{"issue":"Issue 4 Part 2","key":"10.1002\/14651858.CD003715.pub3-BIB0033|cit33","first-page":"A692","article-title":"Maintenance treatment of Crohn's disease: comparative study of 4-aminosalicylic acid and 5-aminosalicylic acid (Claversal) slow release tablets","volume":"102","author":"Schreiber","year":"1992","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD003715.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/gut.35.8.1081","article-title":"Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot sutdy in the maintenance treatment of Crohn's ileocolitis","volume":"35","author":"Schreiber","year":"1994","journal-title":"Gut"},{"key":"10.1002\/14651858.CD003715.pub3-BIB0035|cit35","first-page":"38","article-title":"Results of treatment with sulfasalazine in the American Multicenter Study on the treatment of Crohn disease (National Cooperative Crohn's Disease Study)","volume":"19","author":"Singleton","year":"1981","journal-title":"Zeitschrift fur Gastroenterologie. Verhandlungsband"},{"issue":"11","key":"10.1002\/14651858.CD003715.pub3-BIB0036|cit36","first-page":"A972","article-title":"National cooperative Crohn's disease study (NCCDS): a controlled prospective trial of three drugs vs placebo","volume":"18","author":"Summers","year":"1977","journal-title":"Gut"},{"issue":"4","key":"10.1002\/14651858.CD003715.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National Cooperative Crohn's Disease Study: results of drug treatment","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology"},{"issue":"8044","key":"10.1002\/14651858.CD003715.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(77)90831-5","article-title":"An experiment to determine the active therapeutic moiety of sulphasalazine","volume":"2","author":"Azad Khan","year":"1977","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003715.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-2036.17.s2.20.x","article-title":"Review article: maintenance treatment of Crohn's disease","volume":"17 Suppl 2","author":"Biancone","year":"2003","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"10","key":"10.1002\/14651858.CD003715.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJM197309062891001","article-title":"Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype","volume":"289","author":"Das","year":"1973","journal-title":"New England Journal of Medicine"},{"issue":"22","key":"10.1002\/14651858.CD003715.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators","volume":"342","author":"Feagan","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"12 Suppl","key":"10.1002\/14651858.CD003715.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.amjgastroenterol.2003.11.002","article-title":"Maintenance therapy for inflammatory bowel disease","volume":"98","author":"Feagan","year":"2003","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD003715.pub3-BIB0043|cit43","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008414.pub2","article-title":"Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease","author":"Gordon","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7650","key":"10.1002\/14651858.CD003715.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"9317","key":"10.1002\/14651858.CD003715.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003715.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2036.2004.02048.x","article-title":"Review article: aminosalicylates in inflammatory bowel disease","volume":"20 Suppl 4","author":"Hanauer","year":"2004","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD003715.pub3-BIB0047|cit47","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011. Available from www.cochrane-handbook.org"},{"issue":"26","key":"10.1002\/14651858.CD003715.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJM198012253032602","article-title":"Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease","volume":"303","author":"Klotz","year":"1980","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD003715.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1572-0241.2003.04010.x","article-title":"Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries","volume":"99","author":"Lichtenstein","year":"2004","journal-title":"American Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD003715.pub3-BIB0050|cit50","first-page":"692","article-title":"Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis","volume":"89","author":"Messori","year":"1994","journal-title":"American Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD003715.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/gut.28.2.196","article-title":"Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract","volume":"28","author":"Myers","year":"1987","journal-title":"Gut"},{"issue":"4","key":"10.1002\/14651858.CD003715.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"issue":"12 Suppl","key":"10.1002\/14651858.CD003715.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.amjgastroenterol.2003.10.007","article-title":"Evidence-based treatment algorithm for mild to moderate Crohn's disease","volume":"98","author":"Sandborn","year":"2003","journal-title":"American Journal of Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD003715.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD003715.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/gut.13.4.278","article-title":"Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects","volume":"13","author":"Schroder","year":"1972","journal-title":"Gut"},{"key":"10.1002\/14651858.CD003715.pub3-BIB0056|cit56","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Sch\u00fcnemann","year":"2011. Available from www.cochrane-handbook.org"},{"issue":"12","key":"10.1002\/14651858.CD003715.pub3-BIB0057|cit57","first-page":"2116","article-title":"Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis","volume":"89","author":"Steinhart","year":"1994","journal-title":"American Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD003715.pub3-BIB0058|cit58","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000301","article-title":"Corticosteroids for maintenance of remission in Crohn's disease","author":"Steinhart","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003715.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.0954-6820.1942.tb06841.x","article-title":"Salazopyrin, a new sulfanilamide preparation: A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparation","volume":"110","author":"Svartz","year":"1942","journal-title":"Acta Medica Scandinavica"},{"issue":"7","key":"10.1002\/14651858.CD003715.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/gut.21.7.632","article-title":"Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine","volume":"21","author":"Hees","year":"1980","journal-title":"Gut"},{"issue":"5","key":"10.1002\/14651858.CD003715.pub3-BIB0061|cit61","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000544.pub4","article-title":"Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis","author":"Wang","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD003715.pub3-BIB0062|cit62","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003715.pub2","article-title":"Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn\u2019s disease","author":"Akobeng","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD003715.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T17:07:40Z","timestamp":1718816860000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD003715.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,9,28]]},"references-count":62,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2016,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003715.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,28]]}}}